1. Home
  2. SCLX vs VWAV Comparison

SCLX vs VWAV Comparison

Compare SCLX & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

SELL

Current Price

$3.45

Market Cap

34.4M

Sector

Health Care

ML Signal

SELL

Logo VisionWave Holdings Inc.

VWAV

VisionWave Holdings Inc.

N/A

Current Price

$4.89

Market Cap

36.4M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
SCLX
VWAV
Founded
2011
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
34.4M
36.4M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
SCLX
VWAV
Price
$3.45
$4.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
28.5K
★ 1.3M
Earning Date
11-13-2026
08-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $30,253,000.00
N/A
Revenue This Year
$118.16
N/A
Revenue Next Year
$186.31
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$3.79
$0.26
52 Week High
$27.00
$225.00

Technical Indicators

Market Signals
Indicator
SCLX
VWAV
Relative Strength Index (RSI) 22.30 48.21
Support Level N/A $4.58
Resistance Level $5.60 $6.47
Average True Range (ATR) 0.37 1.18
MACD -0.10 0.15
Stochastic Oscillator 0.93 59.93

Price Performance

Historical Comparison
SCLX
VWAV

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

Share on Social Networks: